mapping better outcomes in advanced nsclc: the patient...

This programme is made possible thanks to educational sponsorship received from Eli Lilly and Company.

Mapping better outcomes in advanced NSCLC: the patient experience

Sunday 27 September • 13:00 – 14:30Messe Wien Exhibition & Congress Center • Strauss

European Cancer Congress Official Sponsored Satellite Symposium @ European Cancer Congress #ECC2015

Mapping better outcomes in advanced NSCLC: the patient experienceEuropean Cancer Congress – Vienna, 2015

Springer Healthcare IME | 3

Contents

4 Programme

5 Welcome message

6 Faculty biographies Nicholas Thatcher

7 Faculty biographies Niels Reinmuth, Cesare Gridelli, Georgio Scagliotti

8 Symposium information

9 Notes


Programme

Time Title Speaker

13:00 – 13:05 Welcome and introduction Nicholas Thatcher (UK)

13:05 – 13:30 Mapping the road: new treatment options in sqNSCLC

Niels Reinmuth (Germany)

13:30 – 13:55 Rerouting to response: overcoming resistance

Cesare Gridelli (Italy)

13:55 – 14:15 The open road: future therapeutic options in NSCLC

Georgio Scagliotti (Italy)

14:15 – 14:30 Panel discussion Faculty

Sunday 27 September 201513:00 – 14:30


Dear Colleagues

Welcome to Vienna and thank you for attending this European Cancer Congress satellite symposium entitled ‘Mapping better outcomes in advanced NSCLC: the patient experience’, which we hope you will find engaging and useful.

The beautiful city of Vienna is famous for its art, culture and architecture. It is also proud to contain the world-famous 650-year-old University of Vienna, which is home to one of the best museums dedicated to the history of Medicine, as well as being able to boast nine Nobel Prize Laureates for Science. World-renowned historical physicians have long come to Vienna to train and study, and many significant medical discoveries have occurred here.

It is with this learning theme in mind that we hope today you gain a further understanding of the pathophysiology, challenges and treatment options within NSCLC.

With several new treatment strategies having been developed, the aim of this symposium is for you to describe the recommended treatment options available for patients who progress while on therapy for advanced NSCLC, and to become familiar with newly approved and advanced experimental treatment options within NSCLC.

Our expert Faculty is looking forward to “walking you down this road” of where we currently are in the fast-moving world of treatment options, as well as exploring further the possibilities for the future. We are anticipating our panel discussion to be a lively and enlightening exchange amongst peers.

We hope that you find this symposium an informative session and would be most grateful for your feedback via the evaluation forms provided within this booklet.

Best wishes,

Nicholas ThatcherSymposium Chair

Welcome message


Faculty biographies

Nicholas Thatcher Symposium ChairProfessor of Oncology, University of Manchester, UK

Nicholas Thatcher is Professor of Oncology at the University of Manchester, in the School of Cancer and Imaging Sciences at the Christie Hospital NHS Trust and Wythenshawe Hospital. His specialty is clinical and translational research in renal cell cancer, melanoma and lung cancer. He was investigator in key clinical trials into chemotherapy methods and dosages in small cell lung cancer and non-small cell lung cancer. He has written several hundred peer-reviewed papers in major scientific medical journals and has directed several PhD theses. He is joint editor of the textbook ‘New Perspectives in Lung Cancer’.


Niels Reinmuth, MD, PhDLungenClinic Grosshansdorf, Grosshansdorf, Germany

Cesare Gridelli, MD, PhD S.G. Moscati Hospital, Avellino, Italy

Georgio Scagliotti, MD, PhD University of Torino, Torino, Italy

Dr Reinmuth is a board-certified Oncologist and Pneumologist. After his residency in Germany and a postdoctoral

fellowship at the UT M.D. Anderson Cancer Center, Houston, Texas, he continued his medical training at the University of Muenster and the University of Heidelberg, Germany. Moreover, he was awarded a post-doctoral lecturing qualification by the University of Heidelberg and the University of Schleswig-Holstein, Germany. Since 2012, Dr Reinmuth has been working as Senior Physician in the Lungenclinic Grosshansdorf, Department for Thoracic Oncology, Grosshansdorf, Germany. He has also been a Co-Principal Investigator (Co-PI) and PI in several clinical trials since 1997. He is member of various medical societies including the German Cancer Society, the German Society of Pulmonology, the International Association for the Study of Lung Cancer, the European Society of Medical Oncology and the American Society of Clinical Oncology.

Dr Gridelli is currently Chief of Division of Medical Oncology and Director of the Department of Oncology/

Hematology at the “S.G. Moscati” Hospital, Avellino, Italy. His areas of expertise are lung cancer and cancer in the elderly. He is deeply involved in the clinical development of new anticancer targeted therapies. He is President of the Italian Association of Thoracic Oncology (AIOT) and is a member of several other national (AIOM, AIOT, CTPG) and international scientific societies (ASCO, ESMO, IASLC). He is a past member of the Foundation Council of the European Thoracic Oncology Platform (ETOP). He is also a member of several Advisory Boards for scientific journals and expert panels. Dr Gridelli has been invited as a Speaker at many international conferences and educational activities of oncology societies (ASCO, ESMO etc). He is author or co-author of more than 750 papers, of which more than 370 are extended papers published in international indexed journals, and several book chapters. His papers have about 15,000 citations in international indexed journals. Dr Gridelli has an h-index of 58.

Dr Scagliotti is currently Professor of Oncology at the University of Torino. Dr Scagliotti earned his medical degree and completed

his postgraduate training in Respiratory Medicine, Internal Medicine, and Medical Oncology at the University of Torino. He is currently Chief of the Medical Oncology Division at the S. Luigi Hospital, and Head of the Department of Oncology at University of Torino, Torino. Dr Scagliotti is a member of several scientific societies, including the Italian Society of Respiratory Medicine, the European Respiratory Society, the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. From 2003 to 2007, he was an Executive Board member of the International Association for the Study of Lung Cancer. He is Associate Editor for the Journal of Thoracic Oncology and International Editor for Clinical Lung Cancer. He is the author or co-author of more than 280 publications in peer-reviewed journals and is the International Editor of the 4th edition of “Lung Cancer: Principles and practice” and co-editor of the IASLC textbook on the multidisciplinary approach to thoracic oncology.


Symposium information

OrganisersThis educational activity has been planned and independently implement by Springer Healthcare IME.

Springer Healthcare IME is the Independent Medical Education group of Springer Healthcare, part of the Springer Science+Business Media global publishing group.

Educational sponsorship This programme is made possible thanks to educational sponsorship received from Eli Lilly and Company.

CMEAn application has been made for CME accreditation of this event.

Filming and photographySpringer healthcare may film or take photographs at the symposium that may be used in publicity and marketing materials. Your attendance at the meeting may mean you are featured in such photographs and films and, unless you notify a member of the Springer Healthcare IME team your objection to this, your consent will be implied.


Notes

This programme is made possible thanks to educational sponsorship received from Eli Lilly and Company

mapping better outcomes in advanced nsclc: the patient...

Documents